Muscle dysmorphia and anabolic-androgenic steroid use

Dave Smith; Mary Caitlyn Rutty; Tracy W. Olrich

doi:10.1057/978-1-137-53535-1_3

Muscle dysmorphia and anabolic-androgenic steroid use

Dave Smith, Mary Caitlyn Rutty, Tracy W. Olrich

Physical Education & Sport

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

7 Scopus citations

Abstract

Substance use is much more common in individuals with body dysmorphic disorder (BDD) than in the general population (Grant et al., Journal of Clinical Psychiatry 66(3):309-405, 2005). In individuals with muscle dysmorphia (MD), a type of BDD that manifests as a pathological preoccupation with muscularity, the use of various substances that are associated with muscle building, such as anabolic steroids is much more prevalent than in the general population (Pope et al., Body Image 2:395-400, 2005). This chapter will examine the links between MD and such drug use, exploring the literature that has examined this issue, discussing treatment issues, and suggesting future research directions.

Original language	English
Title of host publication	Chemically Modified Bodies
Subtitle of host publication	The Use of Diverse Substances for Appearance Enhancement
Publisher	Palgrave Macmillan
Pages	31-50
Number of pages	20
ISBN (Electronic)	9781137535351
ISBN (Print)	9781137535344
DOIs	https://doi.org/10.1057/978-1-137-53535-1_3
State	Published - Jan 1 2016

Access to Document

10.1057/978-1-137-53535-1_3

Cite this

@inbook{341d9f0e93404ebcbaccfd20a32030d4,

title = "Muscle dysmorphia and anabolic-androgenic steroid use",

abstract = "Substance use is much more common in individuals with body dysmorphic disorder (BDD) than in the general population (Grant et al., Journal of Clinical Psychiatry 66(3):309-405, 2005). In individuals with muscle dysmorphia (MD), a type of BDD that manifests as a pathological preoccupation with muscularity, the use of various substances that are associated with muscle building, such as anabolic steroids is much more prevalent than in the general population (Pope et al., Body Image 2:395-400, 2005). This chapter will examine the links between MD and such drug use, exploring the literature that has examined this issue, discussing treatment issues, and suggesting future research directions.",

author = "Dave Smith and Rutty, {Mary Caitlyn} and Olrich, {Tracy W.}",

note = "Publisher Copyright: {\textcopyright} The Editor(s) and The Author(s) 2016.",

year = "2016",

month = jan,

day = "1",

doi = "10.1057/978-1-137-53535-1_3",

language = "English",

isbn = "9781137535344",

pages = "31--50",

booktitle = "Chemically Modified Bodies",

publisher = "Palgrave Macmillan",

}

TY - CHAP

T1 - Muscle dysmorphia and anabolic-androgenic steroid use

AU - Smith, Dave

AU - Rutty, Mary Caitlyn

AU - Olrich, Tracy W.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Substance use is much more common in individuals with body dysmorphic disorder (BDD) than in the general population (Grant et al., Journal of Clinical Psychiatry 66(3):309-405, 2005). In individuals with muscle dysmorphia (MD), a type of BDD that manifests as a pathological preoccupation with muscularity, the use of various substances that are associated with muscle building, such as anabolic steroids is much more prevalent than in the general population (Pope et al., Body Image 2:395-400, 2005). This chapter will examine the links between MD and such drug use, exploring the literature that has examined this issue, discussing treatment issues, and suggesting future research directions.

AB - Substance use is much more common in individuals with body dysmorphic disorder (BDD) than in the general population (Grant et al., Journal of Clinical Psychiatry 66(3):309-405, 2005). In individuals with muscle dysmorphia (MD), a type of BDD that manifests as a pathological preoccupation with muscularity, the use of various substances that are associated with muscle building, such as anabolic steroids is much more prevalent than in the general population (Pope et al., Body Image 2:395-400, 2005). This chapter will examine the links between MD and such drug use, exploring the literature that has examined this issue, discussing treatment issues, and suggesting future research directions.

UR - http://www.scopus.com/inward/record.url?scp=85017633748&partnerID=8YFLogxK

U2 - 10.1057/978-1-137-53535-1_3

DO - 10.1057/978-1-137-53535-1_3

M3 - Chapter

AN - SCOPUS:85017633748

SN - 9781137535344

SP - 31

EP - 50

BT - Chemically Modified Bodies

PB - Palgrave Macmillan

ER -

Muscle dysmorphia and anabolic-androgenic steroid use

Abstract

Access to Document

Other files and links

Fingerprint

Cite this